Abstract
The randomized phase III PAOLA-1 study (NCT02477644) showed that addition of olaparib to bev maintenance improved progression-free survival (PFS) in pts with advanced OC (Ray-Coquard et al. NEJM 2019). We evaluated maintenance olaparib plus bev in the older subgroup of PAOLA-1 pts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have